secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001140361-26-011862
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports FY2025 net loss of $34.5M, updates PDS0101 Phase 3 with interim PFS endpoint
--------------------------------------------------------------------------------

- Net loss of $34.5M ($0.74/share) vs $37.6M ($1.03/share) in 2024; cash $26.7M at year-end.
- Amended VERSATILE-003 Phase 3 protocol to add PFS as interim endpoint; aims for accelerated approval and reduced trial cost.
- PDS01ADC in mCRPC showed median PFS 9.6 months, PSA decline 40% in early NCI-led Phase 2 data.
- New US and Japan patents for PDS0101 extend market protection into 2040s.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/0001140361-26-011862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/ef20069202_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-011862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer